Special Issue

Pharmacological Therapies for Stress-Related Disorders and Autism Spectrum Disorder

Message from the Guest Editors

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the first choice as pharmacological treatment of anxiety disorder in the general population. Depression disorder is a common heterogeneous mental disease that affects all aspects of patients' lives, as well as people around them. Nowadays. ADs are divided into five classes: SSRIs, SNRIs, TCAs, MAOIs and atypical ADs with unique mechanisms of action. The development of new drugs and methods for depression treatment is critical. The current therapy for anxiety in ASD includes cognitive-behavioral therapy and psychopharmacological treatment. In this Special Issue, we want to expand the knowledge on antidepressant drugs and their mechanism of action. Pharmacological interventions show promise for typically developing populations, but further research is needed to establish the efficacy of medications for individuals. Because comorbid ASD/anxiety remains a nascent and developing area of study, practitioners are encouraged to publish the latest scientific findings.

Guest Editors

Dr. Anita Kovács

Medical School, Institute of Physiology, University of Pécs, Szigeti Str. 12, P.O. Box 99, 7602 Pécs, Hungary

Dr. Attila Tóth

Medical School, Institute of Physiology, University of Pécs, Szigeti Str. 12, P.O. Box 99, 7602 Pécs, Hungary

Deadline for manuscript submissions

closed (25 October 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/194483

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

